Longport, Inc. (OTCPK: LPTI)
Health Care · Biotechnology · US
$—
— today · — 1Y
Longport, Inc. (OTCPK: LPTI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $23.00 and employs 8 people.
trading between 0.00 and 0.00.
Tweenvest scores Longport, Inc. across four factors: value 25/100. Its strongest factor is value.
LPTI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.00
- Revenue (TTM)
- $1.19M
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 44.59
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 23.08M
- Employees
- 8
- Next earnings
- —
About Longport, Inc.
Longport, Inc. focuses on the creation, production, promotion, and distribution of advanced high-resolution ultrasound imaging equipment. Although its primary market is the United States, the company also engages in international exports. A notable product is the EPISCAN I-200, a high-frequency ultrasound system designed to visualize the skin and underlying soft tissue using frequencies ranging from 20 to 50 MHz. These versatile devices are utilized across numerous medical and other domains, including the evaluation and prevention of wounds, clinical dermatology, aesthetic and plastic surgery, burn assessment, superficial musculoskeletal imaging, and veterinary applications. Established in 1993, Longport, Inc. is headquartered in Chadds Ford, Pennsylvania.
- ISIN
- US5431371039
- Founded
- 1993
- Listed since
- Jul 24, 2009
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.51 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.76 | +0.10% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.40 | -0.49% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.05 | -0.18% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $835.68 | +0.20% |
| argenx SEENXTBR: ARGX | $65.85B | €877.20 | -2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.41 | +0.23% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.